Non-targeted BTZ-NPs demonstrated greater tumor growth inhibition than free BTZ; however, BCMA-BTZ-NPs induced the highest tumor growth reduction (p < 0.0001 for Non-Targeted vs. Targeted) (Fig. 7A), associated with the longest survival (p < 0.01 for Non-Targeted vs. Targeted) (Fig. 7B), and without effects on host condition (Fig. 7C), or body weight (Fig. 7D). The gene discussed is CASC3; the disease is neoplasm.